Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
ESTEVE Pharmaceuticals SAS
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06541184CT.gov Ziconotide for Non-cancer Pain by Intrathecal Administration | — | Recruiting | — | — | — |
NCT01888120CT.gov Patient Registry of Intrathecal Ziconotide Management(PRIZM) | — | Completed | — | — | — |
NCT00996983CT.gov Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Pain Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ziconotide (this asset) | ESTEVE Pharmaceuticals SAS | P2 | CCC · 53 |
| (±)-Tramadol | EMS | P4 | BBB |
| Lidocaine | National and Kapodistrian University of Athens | P4 | BBB |
| Methadone | Cari Health Inc. | P4 | BBB |
| Fentanyl | Aga Khan University | P4 | BBB |
| Nepenthe | Bursa City Hospital | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Stanford University | P4 | BBB |
| Pregabalin | Federico II University | P4 | BBB |
| Jnj-54135419 | Beijing Tiantan Hospital | P4 | BBB |
+42 more in the Chronic Pain Syndrome cohort
Other indications for Ziconotide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peripheral Neuropathy | — | P4 | BB · 69 |
| Neuralgia | — | P4 | BB · 66 |
| Spinal Cord Disorder | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ziconotide in Chronic Pain Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ziconotide-chronic-pain-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →